Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy

Background: Oral octreotide capsules (OOC; MYCAPSSA(®)) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately contro...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Fleseriu, Maria, Dreval, Akexander V, Pokramovich, Yulia, Bondar, Irina, Isaeva, Elena, Molitch, Mark E, Macut, Djuro P, Leonova, Nina, Raverot, Gerald, Gilgun-Sherki, Yossi, Ludlam, William H, Patou, Gary, Haviv, Asi, Gordon, Murray B, Verbovoy, Andrey, Dogadin, Sergey A, Biermasz, Nienke, Strasburger, Christian J, Melmed, Shlomo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2021
Pynciau:
Neuroendocrinology and Pituitary
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090659/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1058
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg